The ongoing brain tumor lawsuit against Pfizer, the maker of Depo-Provera, has grown immensely within the past year. Survivors have filed thousands of new claims in record-breaking time because of recent developments—and, according to legal experts, many more women are expected to join the lawsuit in the next few months.
The lawsuit started in 2024 after a landmark study revealed a major link between Depo-Provera and an increased risk of brain tumors, finding that shot users were up to 5.6x more likely to develop a tumor called a meningioma. Dozens of women began filing claims shortly after, demanding that Pfizer compensate victims for its failure to warn the public about Depo-Provera’s potential medical risks.
Below is some of the latest news from the Depo-Provera lawsuit, in order from most to least recent.
Mar 2026: Depo-Provera Claims Surge
In just four months, the Depo-Provera lawsuit has skyrocketed from just under 1,500 claims to over 3,500—more than DOUBLE where it was in December 2025. This is a staggering increase in claims rarely seen in product liability law, making Depo-Provera one of the fastest-growing lawsuits of 2026.
Legal experts believe the majority of these claims may have been filed in response to a recent FDA ruling in December, which updated the official Depo-Provera warning label to include meningioma risks.
Dec 2025: The FDA Approves Updated Depo Warning Label
Though it took months of waiting, the U.S. Food and Drug Administration granted Pfizer’s request to update the official Depo-Provera warning label in mid-December. The new warning label provides additional notice to doctors and patients about the Depo shot’s association with meningiomas:
“Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if meningioma is diagnosed.”
According to legal experts, Pfizer likely updated the label to prevent future survivors from claiming that they weren’t warned about Depo-Provera’s risks. However, as new Depo-Provera claims continue to be filed without any obstructions, it’s becoming increasingly clear that this strategy might not work quite like Pfizer intended.
Attorneys are also learning through old studies and international regulations that Pfizer may have actually known about Depo-Provera being linked to meningiomas for decades, even though the company claims to have only found out recently. If this proves to be true, then it would demolish Pfizer’s legal argument that it warned patients about Depo-Provera’s risks in an adequate and timely manner.
Sept 2025: New JAMA Neurology Study Finds Meningioma Risk
One year after the BMJ published its landmark Depo-Provera study, the highly-accredited medical journal JAMA Neurology released its own research to the public. This study reached similar findings as the BMJ in 2024, identifying a 2.43x increased risk of meningioma associated with long-term Depo use.
Researchers for the JAMA Neurology study also discovered two groups of Depo-Provera users that may be at an especially high risk of developing a meningioma:
1. Women who started taking Depo-Provera at the age of 31 or later.
2. Patients who were on Depo-Provera for at least four years or longer.
This new research—along with the 2024 BMJ study—has created a strong scientific foundation for meningioma survivors who’ve been affected, strengthening current and future cases as the Depo-Provera lawsuit continues to progress.
File a Depo-Provera claim
If you or a family member were diagnosed with a meningioma after getting at least one injection of Depo-Provera, you may be entitled to significant compensation from the lawsuit.
Ready for a free case review? Take our online Depo-Provera eligibility evaluation to see if you may be eligible to file a claim.
